Further Development and Validation of the Cerebellar Neuropsychiatric Rating Scale (CNRS)
There are many scales that assess the disruption of drive, motivation, mood, impulsivity, anxiety, and social cognition, in patients with psychiatric illness. However, no single scale covers the issues that we have identified in the cerebellar patient population. There is not a scale to assess the emotional component of the Cerebellar Cognitive Affective Syndrome (CCAS), and this highlights a lack a sensitivity of current exams regarding patients with cerebellar disorders.
We aim to further validate a neuropsychiatric rating scale that is sensitive to the neuropsychiatric issues experienced by patients with injuries or degenerations involving the cerebellum.
Link to Enroll: https://redcap.partners.org/redcap/surveys/?s=XCKPAH977ETHAMTJ
About the Study
Eligible Ataxia Types
Spinocerebellar Ataxias (All Types)
Type of Study
Survey
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
07/08/2021
Estimated Completion Date
07/01/2026
IRB Approval #
2021P000808
Location(s)
Online study
Massachusetts General Hospital
101 Merrimac Street, Suite 300
Boston, MA
Contact Information
Anna Burt
aburt2@mgh.harvard.edu
617-726-2476
What does participation in the study entail?
We will ask you to complete an online survey and brief clinical information and demographics forms. Total time should be about 10-15 minutes.
What are the potential benefits for participants?
There are no direct benefits to participants, however there are expected benefits to science that include a detailed understanding of how best to test for neuropsychiatric problems in cerebellar diseases in a clinical setting.
What are the potential risks for participants?
There are no clear risks associated with neuropsychiatric testing. You may experience some anxiety while filling out the scale.
Is there financial compensation?
No.
Is there travel reimbursement?
No.
Who is eligible?
We are looking to study people who are 18 years old and above, who are diagnosed with ataxia and are English-speaking. This is a new study. We invite you to participate, even if you have already participated in an earlier version of this study.
Additional Information or Resources
Link to Enroll: https://redcap.partners.org/redcap/surveys/?s=XCKPAH977ETHAMTJ
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
